BFA Law is Investigating ADMA BIOLOGICS for Securities Fraud after Stock Plummets 20%; Contact the Firm if You Suffered Losses (Nasdaq:ADMA)

Company Overview - ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets, and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases [1] Stock Performance - ADMA Biologics stock experienced a significant decline of more than 20% during trading on October 10, 2024, following the surprise resignation of its independent outside auditor, CohnReznick LLP, on October 9, 2024 [2] Legal Investigation - Leading securities law firm Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potential violations of federal securities laws [1] - Investors in ADMA Biologics are encouraged to obtain additional information and may have legal options to submit their information to the firm [2][3] Law Firm Background - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and shareholder litigation [3] - The firm has a notable track record, including recovering over $900 million from Tesla, Inc's Board of Directors and$420 million from Teva Pharmaceutical Ind Ltd [3]